113 related articles for article (PubMed ID: 2786529)
1. A monoclonal antibody to the IL-1 beta peptide 163-171 blocks adjuvanticity but not pyrogenicity of IL-1 beta in vivo.
Boraschi D; Volpini G; Villa L; Nencioni L; Scapigliati G; Nucci D; Antoni G; Matteucci G; Cioli F; Tagliabue A
J Immunol; 1989 Jul; 143(1):131-4. PubMed ID: 2786529
[TBL] [Abstract][Full Text] [Related]
2. Defining the structural requirements of a biologically active domain of human IL-1 beta.
Boraschi D; Antoni G; Perin F; Villa L; Nencioni L; Ghiara P; Presentini R; Tagliabue A
Eur Cytokine Netw; 1990; 1(1):21-6. PubMed ID: 2102359
[TBL] [Abstract][Full Text] [Related]
3. Mapping of biologically relevant sites on human IL-1 beta using monoclonal antibodies.
Massone A; Baldari C; Censini S; Bartalini M; Nucci D; Boraschi D; Telford JL
J Immunol; 1988 Jun; 140(11):3812-6. PubMed ID: 3259598
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of IL-1 beta activities and receptor binding by monoclonal antibodies mapping within a discrete region of the protein.
Boraschi D; Villa L; Ghiara P; Presentini R; Bossù P; Censini S; Nucci D; Massone A; Rossi R; Flad HD
Lymphokine Cytokine Res; 1991 Oct; 10(5):377-84. PubMed ID: 1722713
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant activity of the 163-171 peptide of human IL-1 beta administered through different routes.
Nencioni L; Villa L; Tagliabue A; Boraschi D
Lymphokine Res; 1987; 6(4):335-9. PubMed ID: 3501509
[TBL] [Abstract][Full Text] [Related]
6. Defining agonist peptides of human interleukin-1 beta.
Tagliabue A; Antoni G; Boraschi D
Lymphokine Res; 1989; 8(3):311-5. PubMed ID: 2789323
[TBL] [Abstract][Full Text] [Related]
7. Antiidiotypic antibodies mimic molecular and functional properties of human IL-1 beta in vitro and in vivo.
Soprana E; Vigo E; Verani A; Blom J; Siccardi AG; Vercelli D; Viale G
Lymphokine Cytokine Res; 1994 Oct; 13(5):325-30. PubMed ID: 7858065
[TBL] [Abstract][Full Text] [Related]
8. Rabbit IL-1. Cloning, expression, biologic properties, and transcription during endotoxemia.
Cannon JG; Clark BD; Wingfield P; Schmeissner U; Losberger C; Dinarello CA; Shaw AR
J Immunol; 1989 Apr; 142(7):2299-306. PubMed ID: 2784458
[TBL] [Abstract][Full Text] [Related]
9. A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity.
Antoni G; Presentini R; Perin F; Tagliabue A; Ghiara P; Censini S; Volpini G; Villa L; Boraschi D
J Immunol; 1986 Nov; 137(10):3201-4. PubMed ID: 3490514
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 and interleukin-1 fragments as vaccine adjuvants.
Boraschi D; Tagliabue A
Methods; 1999 Sep; 19(1):108-13. PubMed ID: 10525446
[TBL] [Abstract][Full Text] [Related]
11. Increasing the immunogenicity of protein antigens through the genetic insertion of VQGEESNDK sequence of human IL-1 beta into their sequence.
Beckers W; Villa L; Gonfloni S; Castagnoli L; Newton SM; Cesareni G; Ghiara P
J Immunol; 1993 Aug; 151(4):1757-64. PubMed ID: 8345181
[TBL] [Abstract][Full Text] [Related]
12. Human interleukin 1: structure-function relationship.
Boraschi D; Tagliabue A
Ann Ist Super Sanita; 1990; 26(3-4):273-82. PubMed ID: 2091500
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antipeptide antibodies recognize IL-3 and neutralize its bioactivity in vivo.
Ziltener HJ; Clark-Lewis I; Fazekas de St Groth B; Orban PC; Hood LE; Kent SB; Schrader JW
J Immunol; 1988 Feb; 140(4):1182-7. PubMed ID: 3257773
[TBL] [Abstract][Full Text] [Related]
14. Generation of monoclonal antibodies to murine IL-1 beta and demonstration of IL-1 in vivo.
Hogquist KA; Nett MA; Sheehan KC; Pendleton KD; Schreiber RD; Chaplin DD
J Immunol; 1991 Mar; 146(5):1534-40. PubMed ID: 1993843
[TBL] [Abstract][Full Text] [Related]
15. Identification of functional domains in murine granulocyte-macrophage colony-stimulating factor using monoclonal antibodies to synthetic peptides.
Greenfield RS; Braslawsky GR; Kadow KF; Spitalny GL; Chace D; Bull CO; Bursuker I
J Immunol; 1993 Jun; 150(12):5241-51. PubMed ID: 8515057
[TBL] [Abstract][Full Text] [Related]
16. A rat monoclonal antibody that binds specifically to mouse T lymphoblasts and inhibits IL 2 receptor functions: a putative anti-IL 2 receptor antibody.
Osawa H; Diamantstein T
J Immunol; 1984 May; 132(5):2445-50. PubMed ID: 6425405
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against a peptide representative of a conserved region of human IFN-alpha. Differential effects on the antiviral and antiproliferative effects of IFN.
Barasoain I; Portolés A; Aramburu JF; Rojo JM
J Immunol; 1989 Jul; 143(2):507-12. PubMed ID: 2738400
[TBL] [Abstract][Full Text] [Related]
18. In vivo immunostimulating activity of the 163-171 peptide of human IL-1 beta.
Nencioni L; Villa L; Tagliabue A; Antoni G; Presentini R; Perin F; Silvestri S; Boraschi D
J Immunol; 1987 Aug; 139(3):800-4. PubMed ID: 2955051
[TBL] [Abstract][Full Text] [Related]
19. Mapping of receptor binding sites on IL-1 beta by reconstruction of IL-1ra-like domains.
Boraschi D; Bossù P; Ruggiero P; Tagliabue A; Bertini R; Macchia G; Gasbarro C; Pellegrini L; Melillo G; Ulisse E; Visconti U; Bizzarri C; Del Grosso E; Mackay AR; Frascotti G; Frigerio F; Grifantini R; Grandi G
J Immunol; 1995 Nov; 155(10):4719-25. PubMed ID: 7594472
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin peptide SFGSGFGGGY mimics N-acetyl-beta-D-glucosamine in reaction with antibodies and lectins, and induces in vivo anti-carbohydrate antibody response.
Shikhman AR; Greenspan NS; Cunningham MW
J Immunol; 1994 Dec; 153(12):5593-606. PubMed ID: 7527445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
